Massachusetts
Quiénes somos
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors (AMPLIFY-201)
Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study
Estudio de TAS-102 más radioterapia para el tratamiento del hígado en pacientes con metástasis hepáticas de cáncer colorrectal
A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody Botensilimab in Advanced Cancer
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer Without Liver Metastases
Phase 2 Study of DKN-01 in Colorectal Cancer
Un estudio de combinación de dosis fija de nivolumab-relatlimab frente a regorafenib o TAS-102 en participantes con cáncer colorrectal metastásico de última línea
